Integra LifeSciences Holdings Corporation $IART Shares Acquired by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 71.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,414,509 shares of the life sciences company's stock after buying an additional 589,408 shares during the quarter. Bank of America Corp DE owned approximately 1.82% of Integra LifeSciences worth $13,325,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock valued at $889,000 after acquiring an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Integra LifeSciences during the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. grew its position in shares of Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock worth $36,515,000 after acquiring an additional 35,790 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock valued at $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Integra LifeSciences in the 2nd quarter valued at approximately $491,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. BMO Capital Markets initiated coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a "market perform" rating and a $19.00 target price on the stock. Wells Fargo & Company increased their price target on Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 30th. UBS Group initiated coverage on Integra LifeSciences in a report on Tuesday, July 28th. They set a "neutral" rating and a $19.00 price target on the stock. Truist Financial lifted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a "hold" rating in a research note on Thursday, July 16th. Finally, Citigroup reaffirmed a "neutral" rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of "Reduce" and an average price target of $18.86.

Integra LifeSciences Trading Up 0.9%

NASDAQ IART opened at $16.74 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $20.49. The firm's fifty day simple moving average is $17.99 and its 200-day simple moving average is $14.05. The company has a market capitalization of $1.30 billion, a PE ratio of -185.98, a price-to-earnings-growth ratio of 1.40 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The firm had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source